Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (60)	8/16/2002 11:18:41 AM
From: tuck	Respond to of 510

>>Cancer Res 2002 Jul 1;62(13):3609-14 Related Articles, Books, LinkOut Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia 23501, USA. The prostate-specific antigen test has been a major factor in increasing awareness and better patient management of prostate cancer (PCA), but its lack of specificity limits its use in diagnosis and makes for poor early detection of PCA. The objective of our studies is to identify better biomarkers for early detection of PCA using protein profiling technologies that can simultaneously resolve and analyze multiple proteins. Evaluating multiple proteins will be essential to establishing signature proteomic patterns that distinguish cancer from noncancer as well as identify all genetic subtypes of the cancer and their biological activity. In this study, we used a protein biochip surface enhanced laser desorption/ionization mass spectrometry approach coupled with an artificial intelligence learning algorithm to differentiate PCA from noncancer cohorts. Surface enhanced laser desorption/ionization mass spectrometry protein profiles of serum from 167 PCA patients, 77 patients with benign prostate hyperplasia, and 82 age-matched unaffected healthy men were used to train and develop a decision tree classification algorithm that used a nine-protein mass pattern that correctly classified 96% of the samples. A blinded test set, separated from the training set by a stratified random sampling before the analysis, was used to determine the sensitivity and specificity of the classification system. A sensitivity of 83%, a specificity of 97%, and a positive predictive value of 96% for the study population and 91% for the general population were obtained when comparing the PCA versus noncancer (benign prostate hyperplasia/healthy men) groups. This high-throughput proteomic classification system will provide a highly accurate and innovative approach for the early detection/diagnosis of PCA.<< snip Cheers, Tuck

To: tuck who wrote (60)	8/19/2002 4:26:18 PM
From: tuck	Read Replies (2) \| Respond to of 510

I was keying on this phrase from the earnings PR this morning . . . >>Accelerating Patent Activities. Ciphergen filed 7 new patent applications in the second quarter, more than in any previous quarter. Many of these applications are directed to multiple biomarkers and assays resulting from work with our research collaborators. Since the beginning of 2002, Ciphergen has filed 12 new patent applications.<< A search at the PTO turned up one patent application related to biomarkers, pertaining to endometrial cancer diagnosis. It was filed by GL Mutter from Harvard, a collaborator and user of PBS', but Ciphergen was not an assignee (#20020106662). There are several involving mitochondria which seem mostly to be produced by MitoKor here in San Diego, apparently a customer, and one that wants to IPO. Then there was a patent application having to do with "concentration" and "no-wash" SELDI, which appear to be improvements that allow for greater sensitivity versus MALDI(#20020060290). Ciphergen is the assignee for this one. Sure would like to find these biomarker patents they're talking of. Cheers, Tuck